Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.6%

3 terminated/withdrawn out of 22 trials

Success Rate

84.2%

-2.3% vs industry average

Late-Stage Pipeline

41%

9 trials in Phase 3/4

Results Transparency

25%

4 of 16 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

9(47.4%)

Phase 2

7(36.8%)

Phase 1

3(15.8%)

19Total

Phase 3(9)

Phase 2(7)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT04543994Phase 1Terminated

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

Role: collaborator

NCT04548583Phase 1Terminated

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

Role: collaborator

NCT02032004Phase 3Completed

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

Role: lead

NCT00877903Phase 2Completed

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Role: lead

NCT00543374Phase 3Completed

Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

Role: lead

NCT00690066Phase 2Completed

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Role: lead

NCT00683722Phase 2Completed

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT00482092Phase 3Completed

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Role: lead

NCT01233960Phase 3Completed

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Role: lead

NCT00284986Phase 2Completed

Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants

Role: lead

NCT01781390Phase 2Completed

Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction

Role: lead

NCT04371393Phase 3Terminated

MSCs in COVID-19 ARDS

Role: collaborator

NCT02336230Phase 3Completed

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Role: lead

NCT02652130Phase 3Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Role: lead

NCT00366145Phase 3Completed

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Role: lead

NCT00136903Phase 2Completed

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Role: lead

NCT00562497Phase 3Completed

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

Role: lead

NCT00294112Phase 2Completed

Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

Role: lead

NCT01510431Unknown

Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease

Role: lead

NCT00114452Phase 1Completed

Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction

Role: lead